{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T16:19:41Z","timestamp":1758817181458},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.iac.2018.04.014","type":"journal-article","created":{"date-parts":[[2018,6,9]],"date-time":"2018-06-09T21:27:17Z","timestamp":1528579637000},"page":"341-350","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["New Insights into Clonal Mast Cell Disorders Including Mastocytosis"],"prefix":"10.1016","volume":"38","author":[{"given":"Sofija","family":"Volertas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"IV","given":"Charles F.","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cem","family":"Akin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.iac.2018.04.014_bib1","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1158\/0008-5472.CAN-16-2234","article-title":"Advances in the classification and treatment of mastocytosis: current status and outlook toward the future","volume":"77","author":"Valent","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.iac.2018.04.014_bib2","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.iac.2018.04.014_bib3","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.iac.2018.04.014_bib4","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1056\/NEJMra1409760","article-title":"Mast cells, mastocytosis, and related disorders","volume":"373","author":"Theoharides","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iac.2018.04.014_bib5","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.jaip.2017.02.008","article-title":"Risk factor analysis of anaphylactic reactions in patients with systemic mastocytosis","volume":"5","author":"Gulen","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.iac.2018.04.014_bib6","first-page":"323","article-title":"Rare forms of urticaria","volume":"2","author":"Nettleship","year":"1869","journal-title":"Br Med J"},{"key":"10.1016\/j.iac.2018.04.014_bib7","series-title":"B\u00ebitrage zur anatomie und pathogenese der urticaria simplex und pigmentosa Mschr. Prakt. Dermatol. Suppl. Dermatol. Stud., 3","first-page":"9","author":"Unna","year":"1887"},{"key":"10.1016\/j.iac.2018.04.014_bib8","first-page":"426","article-title":"Urticaria pigmentosa; a report of a case with autopsy","volume":"48","author":"Ellis","year":"1949","journal-title":"Arch Pathol (Chic)"},{"key":"10.1016\/j.iac.2018.04.014_bib9","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.iac.2018.04.014_bib10","first-page":"14","article-title":"An unusual tumour of the lung","volume":"107","author":"Ayadi","year":"2015","journal-title":"Pathologica"},{"key":"10.1016\/j.iac.2018.04.014_bib11","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/00043426-200102000-00014","article-title":"Temporary response of localized intracranial mast cell sarcoma to combination chemotherapy","volume":"23","author":"Guenther","year":"2001","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"key":"10.1016\/j.iac.2018.04.014_bib12","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1136\/jcp.39.6.596","article-title":"Mast cell sarcoma of the larynx","volume":"39","author":"Horny","year":"1986","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.iac.2018.04.014_bib13","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s00277-013-1931-x","article-title":"Mast cell sarcoma mimicking metastatic colon carcinoma","volume":"93","author":"Schwaab","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.iac.2018.04.014_bib14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jaci.2015.08.034","article-title":"Cutaneous manifestations in patients with mastocytosis: consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology","volume":"137","author":"Hartmann","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2018.04.014_bib15","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1046\/j.1365-2141.2003.04575.x","article-title":"Diagnosis and treatment of systemic mastocytosis: state of the art","volume":"122","author":"Valent","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.iac.2018.04.014_bib16","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.iac.2018.04.014_bib17","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1182\/blood-2009-10-249979","article-title":"WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults","volume":"115","author":"Pardanani","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.iac.2018.04.014_bib18","series-title":"WHO classification of tumors of haematopoietic and lymphoid tissues","first-page":"61","article-title":"Mastocytosis","author":"Horny","year":"2017"},{"key":"10.1016\/j.iac.2018.04.014_bib19","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1182\/blood-2003-11-3816","article-title":"A\u00a0novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib","volume":"103","author":"Akin","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.iac.2018.04.014_bib20","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jaci.2015.05.008","article-title":"Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis","volume":"137","author":"Alvarez-Twose","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2018.04.014_bib21","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jaci.2009.05.003","article-title":"Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients","volume":"124","author":"Escribano","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2018.04.014_bib22","doi-asserted-by":"crossref","first-page":"e76116","DOI":"10.1371\/journal.pone.0076116","article-title":"Serum tryptase monitoring in indolent systemic mastocytosis: association with disease features and patient outcome","volume":"8","author":"Matito","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.iac.2018.04.014_bib23","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00277-013-1964-1","article-title":"The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis","volume":"93","author":"Erben","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.iac.2018.04.014_bib24","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/all.12409","article-title":"The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease","volume":"69","author":"Hoermann","year":"2014","journal-title":"Allergy"},{"key":"10.1016\/j.iac.2018.04.014_bib25","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1038\/leu.2016.190","article-title":"Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2\/ASXL1\/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis","volume":"30","author":"Jawhar","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.iac.2018.04.014_bib26","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood-2015-07-655100","article-title":"KIT D816V-mutated bone marrow mesenchymal stem cells in indolent systemic mastocytosis are associated with disease progression","volume":"127","author":"Garcia-Montero","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.iac.2018.04.014_bib27","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.1182\/blood-2009-05-220145","article-title":"Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies","volume":"114","author":"Pardanani","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.iac.2018.04.014_bib28","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0145-2126(01)00041-8","article-title":"Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis","volume":"25","author":"Sperr","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.iac.2018.04.014_bib29","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdu047","article-title":"Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal","volume":"25","author":"Valent","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.iac.2018.04.014_bib30","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/all.12436","article-title":"Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis","volume":"69","author":"Valent","year":"2014","journal-title":"Allergy"},{"key":"10.1016\/j.iac.2018.04.014_bib31","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000329856","article-title":"Validation of the REMA score for predicting mast cell clonality and systemic mastocytosis in patients with systemic mast cell activation symptoms","volume":"157","author":"Alvarez-Twose","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.iac.2018.04.014_bib32","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1046\/j.1365-2141.2002.03944.x","article-title":"Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients","volume":"119","author":"Casassus","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.iac.2018.04.014_bib33","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.21561","article-title":"Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine","volume":"84","author":"Lim","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.iac.2018.04.014_bib34","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood-2014-12-614743","article-title":"Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis","volume":"126","author":"Barete","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.iac.2018.04.014_bib35","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.bbmt.2016.04.018","article-title":"Consensus opinion on allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis","volume":"22","author":"Ustun","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.iac.2018.04.014_bib36","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1093\/annonc\/mdx290","article-title":"Midostaurin: a magic bullet that blocks mast cell expansion and activation","volume":"28","author":"Valent","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.iac.2018.04.014_bib37","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iac.2018.04.014_bib38","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood-2017-01-764423","article-title":"Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers","volume":"130","author":"Jawhar","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.iac.2018.04.014_bib39","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/leu.2015.24","article-title":"KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis","volume":"29","author":"Arock","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.iac.2018.04.014_bib40","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0140-6736(16)31403-9","article-title":"Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study","volume":"389","author":"Lortholary","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.iac.2018.04.014_bib41","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1200\/JCO.2011.38.9973","article-title":"Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis","volume":"30","author":"Alvarez-Twose","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.iac.2018.04.014_bib42","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.leukres.2014.07.010","article-title":"Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412","volume":"38","author":"de Melo Campos","year":"2014","journal-title":"Leuk Res"}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856118300420?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856118300420?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,7,14]],"date-time":"2018-07-14T16:42:39Z","timestamp":1531586559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889856118300420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0889856118300420"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2018.04.014","relation":{},"ISSN":["0889-8561"],"issn-type":[{"value":"0889-8561","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New Insights into Clonal Mast Cell Disorders Including Mastocytosis","name":"articletitle","label":"Article Title"},{"value":"Immunology and Allergy Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iac.2018.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}